Skip to main content
. 2022 Aug 25;10(8):e005332. doi: 10.1136/jitc-2022-005332

Figure 1.

Figure 1

(A) Progression-free and (B) overall survival, (C) exceptional responder—partial response with CEA trend and (D) ctDNA Dynamics while on T+D. CEA, carcinoembryonic antigen; ctDNA, circulating tumor DNA.